Tibet Pharmaceutical (600211.SH) announced its performance for the first half of the year, with a net profit attributable to the parent company of 608 million yuan, a year-on-year increase of 7.16%.

Zhuhai Pharmaceutical (600211.SH) released its semi-annual report for 2026. During the reporting period, the company achieved operating revenue of 1.554 billion yuan, a year-on-year decrease of 5.83%. The net profit attributable to shareholders of the listed company was 608 million yuan, a year-on-year increase of 7.16%. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 440 million yuan, a year-on-year decrease of 19.00%. Basic earnings per share were 1.91 yuan.